The Regulatory T Cell-Selective Interleukin-2 Receptor Agonist Rezpegaldesleukin in the Treatment of Inflammatory Skin Diseases: Two Randomized, Double-Blind, Placebo-Controlled Phase Ib Trials

Investigators presented clinical evidence for the regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukinin two randomized, double-blind, placebo-controlled Phase Ib trials in patients with moderate-to-severe atopic dermatitis or chronic plaque psoriasis.